1. Zyban [package insert]. Glaxo Smith Kline; January 2012.
2. Nicotrol Nasal Spray [package insert]. Pfizer; June 2010.
3. Nicotrol Inhaler [package insert]. Pfizer; December 2008.
4. A clinical practice guideline for treating tobacco use and dependence. JAMA. 2000;283:3244-3254.
5. Watts SA, Noble SL, Smith PO, and Disco M. First-line Pharmacotherapy for Tobacco Use and Dependence. JABFP. 2002;15(6):489-497.
6. Anderson JE, Jorenby DE, Scott WJ, and Fiore MC. Treating Tobacco Use and Dependence: An Evidence-Based Clinical Practice Guideline for Tobacco Cessation. Chest. 2002;121:932-941.
7. Dale LC, Glover EF, Sachs DP, et al. Bupropion for Smoking Cessation: Predictors of Successful Outcome. Chest. 2001;119:1357-1364.
8. Chantix [package insert]. Pfizer; January 2012
9. Nicoderm CQ [package insert]. Sanofi Aventis; April 2007.
10. Nicorette [package insert]. Glaxo Smith Kline; February 2012.
11. Chantix [Prescribing Information]. New York, NY: Pfizer; October 2014.
12. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA. 2006;296:56-63.
13. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA. 2006;296:47-55.
14. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation. JAMA. 2006:296:64-71.